SCHEMBL7058862

SCHEMBL7058862

Clc1nncc2sccc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.39
DYRK1A Q13627 2/20 0.39
MAPT P10636 2/20 0.39
ALDH1A1 P00352 1/20 0.39
HPGD P15428 1/20 0.39
PPARG P37231 1/20 0.39
HTT P42858 1/20 0.39
NCOA2 Q15596 1/20 0.39
NCOA1 Q15788 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
NCOA3 Q9Y6Q9 1/20 0.39
LMNA P02545 1/20 0.38
ICAM1 P05362 1/20 0.33
SELE P16581 1/20 0.33
VCAM1 P19320 1/20 0.33
ADRA2A P08913 1/20 0.31
ADRA2B P18089 1/20 0.31
CHEK1 O14757 1/20 0.31
AURKA O14965 1/20 0.31
DAPK3 O43293 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3980727 0.75 KDM4E (0.39) KDM4EDYRK1AMAPTALDH1A1HPGD
SCHEMBL29904691 0.75 KDM4E (0.39) KDM4EDYRK1AMAPTALDH1A1HPGD
SCHEMBL14438006 0.75 KDM4E (0.44) KDM4EMAPTALDH1A1HPGDPPARG
SCHEMBL19117455 0.75 KDM4E (0.39) KDM4EMAPTALDH1A1HPGDPPARG
Water SCHEMBL27273030 0.73 KDM4E (0.38) KDM4EMAPTALDH1A1HPGDPPARG
SCHEMBL27917876 0.72 CYP2A6 (0.39) KDM4EMAPTALDH1A1HPGDPPARG
SCHEMBL7057753 0.71 SCN9A (0.37) MAPTALDH1A1LMNAICAM1SELE
SCHEMBL20631783 0.71 ALDH1A1 (0.41) KDM4EMAPTALDH1A1HPGDPPARG
SCHEMBL18237916 0.71 KDM4E (0.38) KDM4EMAPTALDH1A1HPGDPPARG
SCHEMBL27273033 0.71 KDM4E (0.36) KDM4EMAPTALDH1A1HPGDPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250215004-A1 AZOLO COMPOUNDS FOR TREATMENT OF FIBROTIC DISEASES GEORG-AUGUST-UNIVERSITAET GOETTINGEN STIFTUNG OEFFENTLICHEN RECHTS (DE) 2025-07-03 US disclosed
EP-4559521-A2 AZOLO COMPOUNDS FOR TREATMENT OF FIBROTIC DISEASES Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin (DE) 2025-05-28 EP disclosed
EP-4404931-B1 AZOLO COMPOUNDS FOR TREATMENT OF FIBROTIC DISEASES GEORG AUGUST UNIV GOETTINGEN STIFTUNG OEFFENTLICHEN RECHTS UNIVSMEDIZIN (DE) 2025-04-09 EP disclosed
CN-119233820-A Azo compounds for the treatment of fibrotic diseases 乔治-奥古斯特-哥廷根公法基金会大学的大学医学院 2024-12-31 CN disclosed
WO-2024227701-A1 PYRIDAZINE COMPOUNDS FOR TREATMENT OF FIBROTIC DISEASES Tietze Chemical Consulting UG (haftungsbeschränkt) (DE) 2024-11-07 WO disclosed
EP-4458358-A1 PYRIDAZINE COMPOUNDS FOR ANTIFIBROTIC THERAPY Tietze Chemical Consulting UG (DE) 2024-11-06 EP disclosed
EP-4404931-A1 AZOLO COMPOUNDS FOR TREATMENT OF FIBROTIC DISEASES Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin (DE) 2024-07-31 EP disclosed
WO-2023222865-A1 AZOLO COMPOUNDS FOR TREATMENT OF FIBROTIC DISEASES GEORG-AUGUST-UNIVERSITÄT GÖTTINGEN STIFTUNG ÖFFENTLICHEN RECHTS, UNIVERSITÄTSMEDIZIN (DE) 2023-11-23 WO disclosed
EP-4279074-A1 AZOLO COMPOUNDS FOR TREATMENT OF FIBROTIC DISEASES Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin (DE) 2023-11-22 EP disclosed
WO-2022253326-A1 NLRP3 INFLAMMASOME INHIBITOR AND APPLICATION THEREOF 药捷安康(南京)科技股份有限公司 2022-12-08 WO disclosed
US-20030220365-A1 Cell adhesion-inhibiting antiinflammatory compounds STEWART ANDREW O (US) 2003-11-27 US disclosed
US-6579882-B2 Thieno(2,3-d)pyrimidine derivatives ABBOTT LABORATORIES 2003-06-17 US disclosed
EP-1181296-A1 CELL ADHESION-INHIBITING ANTIINFLAMMATORY COMPOUNDS ABBOTT LABORATORIES (US) 2002-02-27 EP disclosed
US-20010020030-A1 Cell adhesion-inhibiting antiinflammatory compounds ABBVIE INC. 2001-09-06 US disclosed
US-6232320-B1 THIENO(2,3-C)PYRIDINE AND 5H-THIENO(2,3-C)PYRAN DERIATIVES ABBOTT LABORATORIES 2001-05-15 US disclosed
EP-1090009-A2 CELL ADHESION-INHIBITING ANTINFLAMMATORY COMPOUNDS ABBOTT LABORATORIES (US) 2001-04-11 EP disclosed
WO-2000075145-A1 CELL ADHESION-INHIBITING ANTIINFLAMMATORY COMPOUNDS ABBOTT LABORATORIES (US) 2000-12-14 WO disclosed
WO-1999062908-A2 CELL ADHESION-INHIBITING ANTINFLAMMATORY COMPOUNDS ABBOTT LABORATORIES (US) 1999-12-09 WO disclosed
EP-0225182-B1 CEPHALOSPORIN COMPOUNDS ICI PHARMA (FR) 1993-02-10 EP disclosed
EP-0225182-A2 Cephalosporin compounds ICI PHARMA (FR) 1987-06-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010020030-A1 Cell adhesion-inhibiting antiinflammatory compounds ICAM1, VCAM1, EPCAM KDM4E 4588/4885DYRK1A 4879/4885MAPT 3906/4885
US-20250215004-A1 AZOLO COMPOUNDS FOR TREATMENT OF FIBROTIC DISEASES COL1A1, COL14A1, COL2A1 KDM4E 1205/4885DYRK1A 4338/4885MAPT 2369/4885
US-20030220365-A1 Cell adhesion-inhibiting antiinflammatory compounds ICAM1, VCAM1, EPCAM KDM4E 4588/4885DYRK1A 4879/4885MAPT 3906/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.